Pegfilgrastim in Primary Prophylaxis of Febrile Neutropenia in Elderly Patients with Hematological Malignancies-bendamustine and G-CSF Support

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2019 Jan 24

PMID 30671660

Citations 7

Authors

Claudio Cerchione

Amalia De Renzo

Davide Nappi

Maria Di Perna

Roberta Della Pepa

Novella Pugliese

Lucio Catalano

Fabrizio Pane

Marco Picardi

Affiliations

Soon will be listed here.

Citing Articles

Open-labeled, multicenter phase II study of prophylactic administration of pegylated granulocyte colony-stimulating factor in relapsed or refractory multiple myeloma who received pomalidomide-based regimens (KMM170).

Song G, Lee J, Moon J, Kim D, Kim M, Kim H Front Oncol. 2023; 13:1209110.

PMID: 37965454 PMC: 10642200. DOI: 10.3389/fonc.2023.1209110.

Pegfilgrastim in Supportive Care of Hodgkin Lymphoma.

Cerchione C, Nappi D, Romano A, Martinelli G Cancers (Basel). 2022; 14(17).

PMID: 36077600 PMC: 9455015. DOI: 10.3390/cancers14174063.

Analysis of the Safety of Pegfilgrastim Addition in Bleomycin, Etoposide, and Cisplatin Treatment Patients With Germ Cell Tumors.

Nakagawa R, Iwamoto H, Makino T, Kadomoto S, Yaegashi H, Iijima M Front Oncol. 2022; 11:770067.

PMID: 35070973 PMC: 8776647. DOI: 10.3389/fonc.2021.770067.

Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma.

Cerchione C, Nappi D, Martinelli G Support Care Cancer. 2021; 29(11):6973-6980.

PMID: 33990881 PMC: 8464555. DOI: 10.1007/s00520-021-06266-x.

Pegteograstim prophylaxis for chemotherapy-induced neutropenia and febrile neutropenia: a prospective, observational, postmarketing surveillance study in Korea.

Cheon J, Im H, Shin H, Kim I, Lee W, Lee K Support Care Cancer. 2021; 29(9):5383-5390.

PMID: 33683460 DOI: 10.1007/s00520-021-06127-7.

References

Sosa R, Li S, Molony J, Liu J, Stryker S, Collins A . Use of prophylactic growth factors and antimicrobials in elderly patients with cancer: a review of the Medicare database. Support Care Cancer. 2017; 25(10):3123-3132. DOI: 10.1007/s00520-017-3720-x. View

Cerchione C, Nappi D, Di Perna M, Zacheo I, Migliaccio I, Salvatore D . A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide. Clin Case Rep. 2017; 5(4):505-507. PMC: 5378832. DOI: 10.1002/ccr3.773. View

Balducci L, Repetto L . Increased risk of myelotoxicity in elderly patients with non-Hodgkin lymphoma. Cancer. 2003; 100(1):6-11. DOI: 10.1002/cncr.11861. View

Mondello P, Steiner N, Willenbacher W, Cerchione C, Nappi D, Mauro E . Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study. Oncologist. 2018; 23(4):454-460. PMC: 5896707. DOI: 10.1634/theoncologist.2017-0037. View

Cerchione C, De Renzo A, Di Perna M, Pepa R, Pugliese N, Catalano L . Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience. Support Care Cancer. 2016; 25(3):839-845. PMC: 5266775. DOI: 10.1007/s00520-016-3468-8. View